The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lu, Panpan ^a   Qu, Xiying ^a   Shen, Yinzhong ^b   Jiang, Zhengtao ^a   Wang, Pengfei ^a   Zeng, Hanxian ^a   Ji, Haiyan ^a   Deng, Junxiao ^a   Yang, Xinyi ^a   Li, Xian ^a   Lu, Hongzhou ^b   Zhu, Huanzhang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE DERIVATIVE; BIRABRESIB; FUSED HETEROCYCLIC RINGS; PHORBOL ESTER; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROSTRATIN;

CD4+ T LYMPHOCYTE; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ACETANILIDES; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; DRUG INTERACTIONS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; PHORBOL ESTERS; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84963894121     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24100     Document Type: Article

References (75)

1. Li T. S., et al. Long-lasting recovery in CD4 T-cell function, and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351, 1682-1686 (1998
2. Davey R. T. Jr., et al. HIV-1, and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96, 15109-15114 (1999
3. Finzi D., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997
4. Chun T. W., et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94, 13193-13197 (1997
5. Wong J. K., et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997
6. Whitney J. B., et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74-77, doi: 10.1038/nature13594 (2014
7. Eisele E., & Siliciano R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377-388, doi: 10.1016/j. immuni.2012.08.010 (2012
8. Coiras M., Lopez-Huertas M. R., Perez-Olmeda M., & Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7, 798-812, doi: 10.1038/nrmicro2223 (2009
9. Ruelas D. S., & Greene W. C. An integrated overview of HIV-1 latency. Cell 155, 519-529, doi: 10.1016/j.cell.2013.09.044 (2013
10. Archin N. M., et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 12, 750-764, doi: 10.1038/nrmicro3352 (2014
11. Mbonye U., & Karn J. Control of HIV latency by epigenetic, and non-epigenetic mechanisms. Curr HIV Res 9, 554-567 (2011
12. Kumar A., Darcis G., Van Lint C., & Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics 7, 103, doi: 10.1186/s13148-015-0137-6 (2015
13. Budhiraja S., & Rice A. P. Reactivation of latent HIV: do all roads go through P-TEFb? Future Virol 8, doi: 10.2217/fvl.13.52 (2013
14. Ott M., Geyer M., & Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 10, 426-435, doi: 10.1016/j.chom.2011.11.002 (2011
15. Dahabieh M. S., Battivelli E., & Verdin E. Understanding HIV latency: the road to an HIV cure. Annu Rev Med 66, 407-421, doi: 10.1146/annurev-med-092112-152941 (2015
16. Deeks S. G. HIV: Shock, and kill. Nature 487, 439-440, doi: 10.1038/487439a (2012
17. Bosque A., & Planelles V. Induction of HIV-1 latency, and reactivation in primary memory CD4+ T cells. Blood 113, 58-65, doi: 10.1182/blood-2008-07-168393 (2009
18. Richman D. D., et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307, doi: 10.1126/science.1165706 (2009
19. Routy J. P., et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 13, 291-296, doi: 10.1111/j.1468-1293.2011.00975.x (2012
20. Rasmussen T. A., et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells, and T-cell activation. Hum Vaccin Immunother 9, 993-1001, doi: 10.4161/hv.23800 (2013
21. Elliott J. H., et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. Plos Pathog 10, e1004473, doi: 10.1371/journal.ppat.1004473 (2014
22. Spina C. A., et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems, and resting CD4+ T cells from aviremic patients. Plos Pathog 9, e1003834, doi: 10.1371/journal.ppat.1003834 (2013
23. Filippakopoulos P., et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073, doi: 10.1038/nature09504 (2010
24. Dawson M. A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533, doi: 10.1038/nature10509 (2011
25. Li Z., Guo J., Wu Y., & Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41, 277-287, doi: 10.1093/nar/gks976 (2013
26. Shang H. T., et al. Progress, and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol Sin 36, 908-916, doi: 10.1038/aps.2015.22 (2015
27. Banerjee C., et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92, 1147-1154, doi: 10.1189/jlb.0312165 (2012
28. Bartholomeeusen K., Xiang Y., Fujinaga K., & Peterlin B. M. Bromodomain, and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287, 36609-36616, doi: 10.1074/jbc.M112.410746 (2012
29. Zhu J., et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2, 807-816, doi: 10.1016/j.celrep.2012.09.008 (2012
30. Boehm D., et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452-462, doi: 10.4161/cc.23309 (2013
31. Coude M. M., et al. BET inhibitor OTX015 targets BRD2, and BRD4, and decreases c-MYC in acute leukemia cells. Oncotarget 6, 17698-17712 (2015
32. Boi M., et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models, and Synergizes with Targeted Drugs. Clin Cancer Res 21, 1628-1638, doi: 10.1158/1078-0432.CCR-14-1561 (2015
33. Odore E., et al. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clin Pharmacokinet, doi: 10.1007/s40262-015-0327-6 (2015
34. Ding D., et al. Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology 440, 182-189, doi: 10.1016/j.virol.2013.02.022 (2013
35. Jordan A., Bisgrove D., & Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22, 1868-1877, doi: 10.1093/emboj/cdg188 (2003
36. Laird G. M., et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125, 1901-1912, doi: 10.1172/JCI80142 (2015
37. Bullen C. K., et al. New ex vivo approaches distinguish effective, and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20, 425-429, doi: 10.1038/nm.3489 (2014
38. Laird G. M., et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. Plos Pathog 9, e1003398, doi: 10.1371/journal.ppat.1003398 (2013
39. Jiang G., & Dandekar S. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses 31, 4-12, doi: 10.1089/AID.2014.0199 (2015
40. Xing S., & Siliciano R. F. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 18, 541-551, doi: 10.1016/j.drudis.2012.12.008 (2013
41. Biancotto A., et al. Dual role of prostratin in inhibition of infection, and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes, and lymphoid tissue. J Virol 78, 10507-10515, doi: 10.1128/JVI.78.19.10507-10515.2004 (2004
42. Kulkosky J., et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015 (2001
43. Mehla R., et al. Bryostatin modulates latent HIV-1 infection via PKC, and AMPK signaling but inhibits acute infection in a receptor independent manner. Plos One 5, e11160, doi: 10.1371/journal.pone.0011160 (2010
44. Lucera M. B., et al. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics, and efficiency of postentry viral events. J Virol 88, 10803-10812, doi: 10.1128/JVI.00320-14 (2014
45. Razooky B. S., et al. A hardwired HIV latency program. Cell 160, 990-1001, doi: 10.1016/j.cell.2015.02.009 (2015
46. Weinberger L. S., et al. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122, 169-182, doi: 10.1016/j.cell.2005.06.006 (2005
47. He N., et al. HIV-1 Tat, and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell 38, 428-438, doi: 10.1016/j.molcel.2010.04.013 (2010
48. Sobhian B., et al. HIV-1 Tat assembles a multifunctional transcription elongation complex, and stably associates with the 7SK snRNP. Mol Cell 38, 439-451, doi: 10.1016/j.molcel.2010.04.012 (2010
49. Zhou Q., Li T., & Price D. H. RNA polymerase II elongation control. Annu Rev Biochem 81, 119-143, doi: 10.1146/annurevbiochem-052610-095910 (2012
50. Peterlin B. M., & Price D. H. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23, 297-305, doi: 10.1016/j. molcel.2006.06.014 (2006
51. Fong Y. W., & Zhou Q. Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter. Mol Cell Biol 20, 5897-5907 (2000
52. Mbonye U. R., et al. Phosphorylation of CDK9 at Ser175 enhances HIV transcription, and is a marker of activated P-TEFb in CD4(+ ) T lymphocytes. Plos Pathog 9, e1003338, doi: 10.1371/journal.ppat.1003338 (2013
53. Budhiraja S., et al. Cyclin T1, and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol 87, 1211-1220, doi: 10.1128/JVI.02413-12 (2013
54. Rice A. P., & Herrmann C. H. Regulation of TAK/P-TEFb in CD4+ T lymphocytes, and macrophages. Curr HIV Res 1, 395-404 (2003
55. Kaczmarek Michaels K., et al. RNAP II processivity is a limiting step for HIV-1 transcription independent of orientation to, and activity of endogenous neighboring promoters. Virology 486, 7-14, doi: 10.1016/j.virol.2015.08.027 (2015
56. Williams S. A., et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279, 42008-42017, doi: 10.1074/jbc. M402124200 (2004
57. Byun J. S., et al. ELL facilitates RNA polymerase II pause site entry, and release. Nat Commun 3, 633, doi: 10.1038/ncomms1652 (2012
58. Spivak A. M., et al. A pilot study assessing the safety, and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58, 883-890, doi: 10.1093/cid/cit813 (2014
59. Wei D. G., et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLos Pathog 10, e1004071, doi: 10.1371/journal.ppat.1004071 (2014
60. Sogaard O. S., et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency in Vivo. Plos Pathog 11, e1005142, doi: 10.1371/journal. ppat.1005142 (2015
61. Abstracts from the 2014 Conference on Retroviruses, and Opportunistic Infections. March 3-6, 2014. Boston, Massachusetts. Top Antivir Med 22, 4-568 (2014
62. Archin N. M., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi: 10.1038/nature11286 (2012
63. Archin N. M., et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 210, 728-735, doi: 10.1093/infdis/jiu155 (2014
64. Garnier J. M., Sharp P. P., & Burns C. J. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat 24, 185-199, doi: 10.1517/13543776.2014.859244 (2014
65. Gallenkamp D., Gelato K. A., Haendler B., & Weinmann H. Bromodomains, and their pharmacological inhibitors. ChemMedChem 9, 438-464, doi: 10.1002/cmdc.201300434 (2014
66. Jiang G., et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. Plos Pathog 11, e1005066, doi: 10.1371/journal.ppat.1005066 (2015
67. Prins J. M., et al. Immuno-activation with anti-CD3, and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405-2410 (1999
68. Yik J. H., et al. Inhibition of P-TEFb (CDK9/Cyclin T) kinase, and RNA polymerase II transcription by the coordinated actions of HEXIM1, and 7SK snRNA. Mol Cell 12, 971-982 (2003
69. Shi J., & Vakoc C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 54, 728-736, doi: 10.1016/j.molcel.2014.05.016 (2014
70. Jordan A., Defechereux P., & Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity, and response to Tat transactivation. EMBO J 20, 1726-1738, doi: 10.1093/emboj/20.7.1726 (2001
71. Shan L., et al. A novel PCR assay for quantification of HIV-1 RNA. J Virol 87, 6521-6525, doi: 10.1128/JVI.00006-13 (2013
72. Wang P., et al. As2O3 synergistically reactivate latent HIV-1 by induction of NF-kappaB. Antiviral Res 100, 688-697 (2013
73. Platt E. J., et al. Effects of CCR5, and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72, 2855-2864 (1998
74. Ying H., et al. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation, and activation of NF-kappaB. PLos One 7, e48832, doi: 10.1371/journal.pone.0048832 (2012
75. Wang P., et al. Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′ -LTR promoter. Gene Ther 21, 490-495, doi: 10.1038/gt.2014.21 (2014